CLDN3

Across TCGA pan-cancer cohorts, CLDN3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLDN3 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CLDN3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CLDN3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where CLDN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	III,IV	0.923	0.306	.008	12	view →
HNSC	DFS	Tertile	III,IV	0.371	0.914	.024	10	view →
LUAD	OS	Quartile	III,IV	0.826	0.370	.040	6	view →
CCRCC	OS	Tertile	All	1.000	0.914	.023	6	view →
PDAC	OS	Median	All	0.581	0.405	.046	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLDN3–LSCC (OS)

Open the LSCC breakdown →